Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — NWR Virtual Healthcare Conference 2023
33 slides from Anteris Technologies Global's conference presentation, Mar 21, 2023
Slide 1: ASX Announcement: Presentation at NWR Virtual Healthcare Conference
ASX ANNOUNCEMENT 21 March 2023 For personal use only PRESENTATION AT NWR VIRTUAL HEALTHCARE CONFERENCE BRISBANE, Australia and MINNEAPOLIS, USA, Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) is pleased to provide the attached presentation that Mr Wayne Paterson, Chief Executive Office
Slide 2: Investor Presentation March 2023
For personal use only Investor Presentation March 2023 A late-stage development company that has proven clinical results www.anteristech.com | Follow us @anteristech Copyright Anteris Technologies Ltd 2023
Slide 3: Important Notice and Disclaimer
[Disclaimer ] For personal use only IMPORTANT NOTICE AND DISCLAIMER Summary information This presentation has been prepared by Anteris Technologies Limited (the “Company”). It is a presentation of general background information in summary form about the Company’s activities current at the date of th
Slide 4: Disclaimer (Continued): Forward-looking statements
[Disclaimer ] (Continued) For personal use only Forward-looking statements This presentation contains forward looking statements Forward-looking statements can generally be identified by use of words such as “may”, “should”, “could”, “foresee”, “plan”, “aim”, “will”, “expect”, “intend”, “project”, “
Slide 5: Disclaimer (Continued)
[Disclaimer ] (Continued) For personal use only Past performance Past performance is given for illustrative purposes only. It should not be relied on and is not indicative of future performance, including future security prices. Market data Certain market and industry data used in this presentation
Slide 6: Anteris has created a new class of product to treat a fatal disease
[] Anteris has created a new class of product to treat a fatal disease For personal use only Anteris has developed and combined 3 distinct medical technologies that address current unmet medical needs Anteris™ is competing in a USD $10bn market Clinical studies underway are demonstrating superio
Slide 7: Company Milestones
[] Company Milestones For personal use only Mar. 2021 Jun. 2021 Aug. 2021 2017 Nov. 2021 July 2022 Sept. 2022 Future Successful completion of Successfully implanted five Preliminary results proof of concept (POC) animal TAVR patients in a first-in- demonstrating restoration of study testing the viab
Slide 8: Management Team
[Anteris ] Management Team For personal use only Wayne Paterson Matthew McDonnell Christopher Meduri, MD, MPH David St. Denis Chief Executive Officer & Managing Director Chief Financial Officer Chief Medical Officer Chief Operating Officer • Joined Anteris as CEO in 2018 after • Joined Anteris as CF
Slide 9: First in class valve to treat aortic stenosis
[ Anteris ] has developed a first in class valve to treat Aortic stenosis For personal use only Severe Aortic 1 in 8 people over 75 Transcatheter Aortic Valve Replacement (TAVR ) stenosis is fatal if left have Aortic Stenosis untreated in 50% of patients over 2 years Surgical Aortic Valve Replacemen
Slide 10: TAVR market remains significantly under penetrated after a decade
[TAVR ] market remains significantly under penetrated after a decade For personal use only AS Patient population underpenetrated TAVR Market expected to nearly double by 2028 ~1 of 10 Severe AS treated today Global TAVR market size ($B) 2,100 High Risk 6% Intermediate Risk 14% $10.2B +12% 6.3 $5.3B
Slide 11: TAVR Will Account for 87% of AVRs by 2028
[] TAVR Will Account for 87% of AVR’s by 2028 For personal use only U.S. TAVR / Surgical Aortic Stenosis Procedures U.S. TAVR / Surgical Aortic Stenosis Procedures 2021 2028 27,000 13% 63,440 39% 98,870 61% 174,780 87% TAVR Total Surgical (no TAVR) TAVR Total Surgical (no TAVR) Source: Millennium Re
Slide 12: Yesterday's TAVRs Were Not Imagined For Today's Patients
[Yesterday’s ] TAVR’s Were Not Imagined For Today’s Patients For personal use only Designed by physicians from the start, this new class of product is designed to meet the needs of todays patients “Patients need a valve that restores an active lifestyle “Patients need a safe alternative to open hear
Slide 13: Why It Matters
[] For personal use only WHY IT MATTERS 11
Slide 14: Patients Need New Solutions that Last Longer and Work Better
[Patients ] Need New Solutions that Last Longer and Work Better For personal use only By taking a Patient and Physician centric approach we have developed advanced treatments for aortic stenosis PATIENT AGE KEY CONSIDERATIONS Younger patients now eligible Life ~85 years old Expectancy Guidelines Wha
Slide 15: Today's TAVRs Need to Address the Needs of Younger as well as Older Patients
Today’s TAVR’s Need to Address the Needs of Younger as well as Older [Patients ] For personal use only Current Products Fall Short in Two Critical Areas: Low Incidence of Complications Normal Pre-Disease Hemodynamics ! Predictable Procedure Long Term Durability ! (Avoiding SVD HAM HALT Valve in Valv
Slide 16: ADAPT, DurAVR, ComASUR: a new class of product
For personal use only ADAPT ® DurAVR™ ComASUR™ A completely new class of product in the TAVR space that demonstrates superior clinical 14 results
Slide 17: DurAVR THV System is unique at every level
[DurAVR™ ] Transcatheter Heart Valve System is unique at every level For personal use only DurAVR ADAPT ComASUR Single-Piece Aortic Valve Anti-calcification Process Transfemoral Delivery System • Single Piece of Tissue • Superior Anti-calcification • Allows for Precise Placement • Near Normal Hemody
Slide 18: DurAVR – A More Human Like Valve
[DurAVR™ ] – A More “Human Like” Valve For personal use only A new class of Opens wider (45%) product Restoring pre-disease hemodynamics Designed to be anatomically correct and provides a better seal and flow reversal ratio Single piece design provides greater structural integrity and durability Dur
Slide 19: DurAVR Shaped to Perform like Native Aortic Valve
[DurAVR™ ] Shaped to Perform like Native Aortic Valve For personal use only Optimizes flow dynamics, restoring hemodynamic performance Single Piece Three Piece Graphical representation of the 3D single-piece geometry of DurAVR™ THV (left), and standard balloon-expandable TAVI devices (right). VD 200
Slide 20: Compelling results from recent FIH study
[] For personal use only Compelling results from recent FIH study Robust data supporting durability DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ONLY. 18
Slide 21: Exceptional Hemodynamic Results at 30 Days
Exceptional Hemodynamic Results at 30 Days in Balloon Expandable [Platform ] For personal use only Mean annulus size: 22.95 mm Mean Pressure Gradient (MPG) Doppler Velocity Index (DVI) (n=13) (n=13) mmHg mmHg 70.00 0.70 56.00 0.56 0.53 49.25 42.00 0.42 28.00 0.28 0.20 14.00 0.14 9.02 0.00 0.00 Basel
Slide 22: Exceptional Hemodynamic Results at 30 Days: Effective Orifice Area
Exceptional Hemodynamic Results at 30 Days in Balloon Expandable [Platform ] For personal use only Mean annulus size: 22.95 mm Effective Orifice Area Effective Orifice Area Indexed (n=13) (n=13) cm2 Cm2/m2 2.50 1.50 2.00 2.00 1.20 1.15 1.50 0.90 1.00 0.60 0.50 0.27 0.50 0.30 0.00 0.00 Baseline 30 Da
Slide 23: QoL Improvement at 1 year from baseline
[Continued ] QoL Improvement at 1 year from baseline and 30 day results For personal use only 1-Year 6-Minute Walk Test Average Distance Walked (mt) 400 350 326 300 271.6 250 224.6 200 150 100 50 0 Baseline 30 day 1 year 20% 32% 21
Slide 24: DurAVR: First AVR Shown to Restore Normal Aortic Flow
[DurAVR™: ] First AVR Shown to Restore Normal Aortic Flow For personal use only Normal Valve Flow vs DurAVR: No Significant Difference in Flow (p=0.45) Healthy Aortic Valve Post DurAVR THV Flow Displacement (FD) = 12% Flow Displacement (FD) = 14% Flow Reversal Ratio (FRR) = 0% Flow Reversal Ratio (F
Slide 25: Biomimetic performance is needed for a restorative effect
[Biomimetic ] performance is needed for a restorative effect For personal use only Tomorrow’s patients are increasingly younger and need restorative therapy to return to a pre-disease quality and length of life Bioprosthetic Valve Biomimetic Valve Competitor valves look like nature but DurAVR works
Slide 26: DurAVR Demonstrates Superior EOA and MPG
[] For personal use only DurAVR™ Demonstrates Superior EOA and MPG 21mm round fixture Sapien Hydrodynamics DurAVR Hydrodynamics Evolut Hydrodynamics EOA: 2.30 mm2 EOA: 2.83 mm2 EOA: 2.41 mm2 Gradient: 8.8 mmHg Gradient: 5.9 mmHg Gradient: 8.3 mmHg Data on File. Courtesy of Janarthanan Sathananthan B
Slide 27: Feasibility Study on track for completion in Q2 and TCT presentation in Q3
[ ] Feasibility Study is on track for completion in Q2 and presentation at TCT in Q3 Early For personal use only Dec 22 Feb Mar May Jun Jul Sep Ethics Approvals (all sites) Site All 30 Day Preliminary Full Data Initiation Patients Follow Approval Approval Site Budget Approvals Presented Visits Enrol
Slide 28: DurAVR FDA Early Feasibility Study
[ ] DurAVR™ FDA Early Feasibility Study For personal use only Objective Safety and Feasibility of DurAVRTM THV Study Design Single Arm Clinical Trial 15 patients Up to 7 sites (Cleveland Clinic, Columbia Presbyterian, N (patients/sites) Montefiore, U. of Michigan, Abbott Northwestern, Houston Method
Slide 29: Key account focus enables self funding commercial rollout upon launch
[ ] Key account focus enables self funding commercial rollout upon launch For personal use only • Anteris anticipates up to 5% (USD 250-300 million) market share in the first 12 months post launch based on currently proven clinical results (best in class) • TAVR procedures continue to be concentrate
Slide 30: US facilities validated and online
[] For personal use only US facilities validated and online
Slide 31: Institutional Partnerships
[Anteris ] Institutional Partnerships For personal use only Partnering to Define a New Paradigm in Aortic Valve Science 29
Slide 32: Anteris Has Addressed Unmet Medical Needs With A New Class Of Product
Anteris Has Addressed Unmet Medical Needs With A New Class Of [Product ] For personal use only By combining…. • Tissue science (ADAPT®) • Valve design (DurAVR™) • Physician developed delivery system (ComASUR™) Anteris has created a more “human like” aortic valve replacement with results that reflect
Slide 33: For personal use only
[] For personal use only 32
Anteris Technologies — NWR Virtual Healthcare Conference 2023 on 6ix